When was Adaptyv Biosystems founded?

Adaptyv Biosystems was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Adaptyv Biosystems located?

Adaptyv Biosystems is headquartered in Lausanne, Switzerland. It is registered at 251 Little Falls Drive, Wilmington, DE.

How many employees does Adaptyv Biosystems have?

As of Jun 30, 2026, the latest employee count at Adaptyv Biosystems is 35.

Is Adaptyv Biosystems a funded company?

Adaptyv Biosystems is a funded company, having raised a total of $2.62M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 28, 2021.

When was the latest funding round of Adaptyv Biosystems?

Adaptyv Biosystems' latest funding was a $***** Seed round on Feb 14, 2022, with participation from 11 investors.

Where does Adaptyv Biosystems rank among its competitors?

Adaptyv Biosystems ranks 5th amongst 48 active competitors, of which 12 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Phoremost, which secured $12M in Sep, 2024.

Who are the top competitors of Adaptyv Biosystems?

Adaptyv Biosystems' top competitors include 64x Bio, Phoremost and Molcure. Among them, Phoremost secured the most recent funding round in September, 2024.

Adaptyv Biosystems - 2026 Company Profile, Team, Funding & Competitors

Adaptyv Biosystems is a seed company based in Lausanne (Switzerland), founded in 2021 by Daniel Nakhaee Zadeh Gutierrez, Moustafa Houmani and Julian Englert. It operates as a Provider of protein design, synthesis, testing, and validation services. Adaptyv Biosystems has raised $2.62M in funding from Y Combinator and Founderful. The company has 48 active competitors, including 12 funded and 7 that have exited. Its top competitors include companies like 64x Bio, Phoremost and Molcure.

Company Details

Provider of protein design, synthesis, testing, and validation services. It offers a platform for generating experimental data to improve protein designs. The company streamlines protein expression and enables synthesis of designed proteins. Automated workcells profile protein designs for functions and interactions to generate experimental data.

Website: www.adaptyvbio.com/
Email ID: *****@adaptyvbio.com
Phone Number: +41 **********
Registered Address: 251 Little Falls Drive, Wilmington, DE

Key Metrics

Founded Year

2021

Location

Lausanne, Switzerland

Stage

Seed

Total Funding

$2.62M in 4 rounds

Latest Funding Round

Seed, Feb 14, 2022, $*****

Investors

Y Combinator & 13 more

Ranked

5^th among 48 active competitors

Employee Count

35 as on Jun 30, 2026

Similar Companies

Innovaccer & 2348 more

View Adaptyv Biosystems' full profile

Adaptyv Biosystems is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Adaptyv Biosystems Inc CIN: 0001894760 , United States, Active		-	4 (As on Nov 22, 2021)	-

Adaptyv Biosystems has raised a total funding of $2.62M over 4 rounds. Its first funding round was on Apr 28, 2021. Its latest funding round was a Seed round on Feb 14, 2022 for $*****. 11 investors participated in its latest round. Adaptyv Biosystems has 14 institutional investors.

Here is the list of recent funding rounds of Adaptyv Biosystems:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 14, 2022	4554091	Seed	3553961	2272566	8293737	5416623
Aug 04, 2021	2947466	Seed	4989500	6184270	3889460	9288334
Jul 01, 2021	5014993	Grant (prize money)	1381305	8732544	8383253	FIT

Access funding benchmarks and valuations. Sign up today!

View details of Adaptyv Biosystems's funding rounds and investors

The founders of Adaptyv Biosystems are Daniel Nakhaee Zadeh Gutierrez, Moustafa Houmani and Julian Englert.

Here are the details of Adaptyv Biosystems' key team members:

Daniel Nakhaee Zadeh Gutierrez: Co-Founder of Adaptyv Biosystems.
Contact Info: 1 email address
Moustafa Houmani: Co-Founder of Adaptyv Biosystems.
Julian Englert: Co-Founder of Adaptyv Biosystems.
Contact Info: 1 email address

View details of Adaptyv Biosystems's Founder profiles and Board Members

Adaptyv Biosystems' employee count trend

Adaptyv Biosystems has 35 employees as of Jun 26. Here is Adaptyv Biosystems's employee count trend over the years:

Employee count trend for Adaptyv Biosystems

Uncover Adaptyv Biosystems' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adaptyv Biosystems include 64x Bio, Phoremost and Molcure. Here is the list of Top 10 competitors of Adaptyv Biosystems, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	Y Combinator, Fifty Years & 13 others	61/100
2nd	Phoremost 2015, Cambridge (United Kingdom), Series B	Developer of a phenotypic screening platform for drug target discovery	$76.8M	Parkwalk, Amadeus Capital & 13 others	54/100
3rd	Molcure 2013, Tokyo (Japan), Series C	Provider of AI-based platform for drug discovery and design	$11.7M	JAFCO Group, Dai-Ichi Life & 7 others	53/100
4th	Modular Genetics 2000, Woburn (United States), Series B	Developer of a proprietary, automated system for gene engineering and molecular biology	$8.9M	MassVentures, America’s Seed Fund & 2 others	52/100
5th	Adaptyv Biosystems 2021, Lausanne (Switzerland), Seed	Provider of protein design, synthesis, testing, and validation services	$2.62M	ACE & Company, Y Combinator & 12 others	51/100
6th	Rheonix 2008, Ithaca (United States), Series B	Provider of instruments for automated assays	$72.7M	Rand Capital, Cayuga Venture Fund & 11 others	45/100
7th	reMYND 2002, Leuven (Belgium), Series B	Developer of a drug pipeline programs for neurodegenerative diseases	$29.1M	Korys, SFPI & 6 others	43/100
8th	AimedBio 2018, Seoul (South Korea), Public	Developer of screening platform for brain drug discovery and efficacy	-	Samsung Life Science	42/100
9th	Beacon Discovery 2016, San Diego (United States), Acquired	Develops assay platforms to identify GPCR based therapeutics	-	-	39/100
10th	Nanna Therapeutics 2012, Cambridge (United Kingdom), Acquired	Provider of in-vitro directed evolution platform for drug discovery	-	New Wave Ventures, Gov & 1 others	37/100